The company does not provide specific operational details or line of business in the provided excerpt, focusing instead on financial and legal disclosures.

# Company Summary

The provided excerpt does not contain specific details about what the company does, such as its line of business, products, or services. It primarily lists sections of the company's report, including:

- Business overview (Item 1)
- Risk Factors (Item 1A)
- Unresolved Staff Comments (Item 1A)
- Cybersecurity (Item 1C)
- Properties (Item 1C)
- Legal Proceedings (Item 2)
- Mine Safety Disclosures (Item 3)

There are no details regarding the company's operational activities, number of customers, employees, revenue, or income in the provided text.

BioSig Technologies, Inc. is a medical device company specializing in enhanced electrophysiology diagnosis and treatment through its innovative PURE EP™ System.

# BioSig Technologies, Inc. Overview

## Company Profile
**BioSig Technologies, Inc.** is a medical device company focused on improving the standard of care in electrophysiology through its flagship product, the **PURE EP™ System**. Founded in **February 2009** and based in **Westport, Connecticut**, the company aims to enhance the diagnosis and treatment of cardiac arrhythmias with advanced digital signal processing technology.

## Key Products
### PURE EP™ System
- **Type**: FDA 510(k) cleared non-invasive Class II device.
- **Function**: Combines hardware and software for enhanced signal clarity and precision, designed for real-time visualization of intracardiac signals during catheter ablation procedures.
- **Target Users**: Primarily utilized by electrophysiologists in specialized medical environments, such as electrophysiology (EP) laboratories.

### Key Features
- **Enhanced Signal Acquisition**: Captures critical cardiac signals with high fidelity.
- **Integration**: Seamlessly integrates with existing EP lab systems, compatible with various tools such as mapping and robotic systems.
- **Customizable**: Offers software modules and digital filters tailored to clinical needs.
  
## Business Developments
- **Clinical Deployment**: Over **3,000 procedures** performed with the PURE EP™ System across **21 hospitals** involving more than **80 physicians**.
- **Key Collaborators**: Partnerships with renowned institutions, including **Mayo Clinic**, **Cleveland Clinic**, and **Texas Cardiac Arrhythmia Institute**.

## Financials
- **Revenue**: Generated minimal revenue to date, reflecting its early commercialization stage.
- **Losses**: The company reported a **net loss of $28.7 million** for the year ended **December 31, 2023**.
- **Cash Flow**: **Net cash used in operating activities** during the same period was approximately **$17.3 million**.

## Workforce
- As of **April 15, 2024**, BioSig has reduced its workforce significantly to **4 full-time employees** and utilizes **4 key consultants**, following recent layoffs due to financial strains.

## Intellectual Property
- Holds **36 issued utility patents** related to its technology, along with numerous pending applications. The company aims for a strong patent portfolio to safeguard its innovations.

## Market Dynamics
- The global electrophysiology market is estimated to grow from **$8 billion** in 2023 to **$16 billion** by 2028, driven by the increasing prevalence of cardiac arrhythmias and the adoption of advanced diagnostic and treatment technologies.

## Conclusion
BioSig Technologies, Inc. is positioned in a niche segment of the medical device industry, focusing on addressing complex cardiac arrhythmias with its innovative PURE EP™ System. Despite facing significant operational and financial challenges, including substantial losses and a limited workforce, the company continues to strive for growth in a rapidly evolving market.

BioSig Technologies, Inc.

10-K / April 15, 2025

10-K / April 16, 2024

10-K / April 15, 2025

Company Summary